Cover Image
市場調查報告書

Cathepsin B (APPsekuretaze/Cathepsin B1/EC 3.4.22.1):開發平台分析

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363573
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
Cathepsin B (APPsekuretaze/Cathepsin B1/EC 3.4.22.1):開發平台分析 Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 41 Pages
簡介

所謂Cathepsin B (CatB) ,是屬於肽酶的酵素蛋白質之一,為了結合肽以寬廣特異性促進蛋白質的水解。切割在小分子基材中-Arg-Arg-Xaa-的結合。作為內肽酶,並表示二肽酶活動,打開C端肽。

本報告提供Cathepsin B (APPsekuretaze/Cathepsin B1/EC 3.4.22.1的)開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

Cathepsin B (APPsekuretaze/Cathepsin B1/EC 3.4.22.1) :概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發作的企業

  • ALSP, Inc.
  • BioMAS Ltd.
  • Oncomatryx Biopharma, S.L.
  • Phelix Therapeutics, LLC
  • Virobay Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0602TDB

Summary

Global Markets Direct's, 'Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Review, H2 2016', provides in depth analysis on Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
  • The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Overview 6
  • Therapeutics Development 7
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Stage of Development 7
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Therapy Area 8
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Indication 9
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Pipeline Products Glance 10
  • Early Stage Products 10
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Companies 11
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Products under Development by Universities/Institutes 13
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics Assessment 15
  • Assessment by Monotherapy/Combination Products 15
  • Assessment by Mechanism of Action 16
  • Assessment by Route of Administration 17
  • Assessment by Molecule Type 18
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Companies Involved in Therapeutics Development 20
  • ALSP, Inc. 20
  • BioMAS Ltd. 21
  • Oncomatryx Biopharma, S.L. 22
  • Phelix Therapeutics, LLC 23
  • Virobay Inc. 24
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Drug Profiles 25
  • ALP-496 - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • CIBP-4 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • OMTX-001 - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • SAS - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • Small Molecule to Inhibit Cathepsin B for Oncology - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • Small Molecules to Inhibit Cathepsin B for Alzheimer's Disease - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • VBY-129 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • VBY-285 - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • VBY-376 - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • VBY-825 - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Dormant Projects 37
  • Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Featured News & Press Releases 38
  • Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent 38
  • Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference January 25-27 in Santa Fe, New Mexico 38
  • Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 38
  • Appendix 40
  • Methodology 40
  • Coverage 40
  • Secondary Research 40
  • Primary Research 40
  • Expert Panel Validation 40
  • Contact Us 40
  • Disclaimer 41

List of Tables

  • Number of Products under Development for, H2 2016 7
  • Number of Products under Development by Therapy Area, H2 2016 8
  • Number of Products under Development by Indication, H2 2016 9
  • Comparative Analysis by Early Stage Products, H2 2016 10
  • Number of Products under Development by Companies, H2 2016 11
  • Products under Development by Companies, H2 2016 12
  • Number of Products under Investigation by Universities/Institutes, H2 2016 13
  • Products under Investigation by Universities/Institutes, H2 2016 14
  • Assessment by Monotherapy/Combination Products, H2 2016 15
  • Number of Products by Stage and Mechanism of Action, H2 2016 16
  • Number of Products by Stage and Route of Administration, H2 2016 17
  • Number of Products by Stage and Molecule Type, H2 2016 19
  • Pipeline by ALSP, Inc., H2 2016 20
  • Pipeline by BioMAS Ltd., H2 2016 21
  • Pipeline by Oncomatryx Biopharma, S.L., H2 2016 22
  • Pipeline by Phelix Therapeutics, LLC, H2 2016 23
  • Pipeline by Virobay Inc., H2 2016 24
  • Dormant Projects, H2 2016 37

List of Figures

  • Number of Products under Development for, H2 2016 7
  • Number of Products under Development by Therapy Area, H2 2016 8
  • Number of Products under Development by Top 10 Indication, H2 2016 9
  • Comparative Analysis by Early Stage Products, H2 2016 10
  • Assessment by Monotherapy/Combination Products, H2 2016 15
  • Number of Products by Stage and Mechanism of Actions, H2 2016 16
  • Number of Products by Stage and Routes of Administration, H2 2016 17
  • Number of Products by Molecule Types, H2 2016 18
  • Number of Products by Stage and Molecule Type, H2 2016 18
Back to Top